1) 高血圧治療ガイドライン2009 (日本高血圧学会高血圧治療ガイドライン作成委員会/編), 日本高血圧学会, 20009
2) Dahlof, B., et al.:LIFE Study Group. Cardiovascular morbidity and mortality inthe Losartan Intervention For Endpoint reduction in hypertension study(LIFE):a randomised trial against atenolol. Lancet, 359:995-1003, 2002
3) ALLHAT Collaborative Research Group:Major outcomes in high-risk hypertensivepatients randomized to angiotensin-converting enzyme inhibitor or calciumchannel blocker vs diuretic. JAMA, 288:2981-2997, 2002
4) Chobanian, A. V., et al.:The seventh report of the joint national committee onprevention, detection, evaluation, and treatment of high blood pressure. The JNC 7 report. JAMA, 289:2560-2572, 2003
5) Fujita, T., et al.:Cilnidipine versus amlodipine randomised trial for evaluationin renal disease study investigators. Antiproteinuric effect of the calcium channelblocker cilnidipine added to renin-angiotension inhibitor in hypertensivepatients with chronic renal disease. Kidney Int., 72:1543-1549, 2007